The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer

Cancer Epidemiology

Volumn 37, Issue 2, 2013, Pages 186-190

  Gobbi, Paolo G ^a   Bergonzi, Manuela ^a   Comelli, Mario ^a   Villano, Lara ^a   Pozzoli, Donatella ^a   Vanoli, Alessandro ^a   Dionigi, Paolo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Pancreatic cancer; Prognosis; Relative survival; Symptoms; Time to diagnosis

Indexed keywords

FLUOROURACIL; GEMCITABINE; OXALIPLATIN;

ABDOMINAL PAIN; ACINAR CELL CARCINOMA; ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; BILIARY STENT; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; DELAYED DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; SIGNET RING CARCINOMA; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; COMBINED MODALITY THERAPY; DELAYED DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; WEIGHT LOSS;

EID: 84875812016     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2012.12.002     Document Type: Article

References (23)

1. Perini M.V., Montagnini A.L., Jukemura J., Penteado S., Abdo E.E., Patzina R., et al. Clinical and pathological prognostic factors for curative resection for pancreatic cancer. HPB (Oxford) 2008, 10:356-362.
2. Schnelldorfer T., Ware A.L., Sarr M.G., Smyrk T.C., Zhang L., Qin R., et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?. Ann Surg 2008, 247:456-462.
3. Kondo N., Murakami Y., Uemura K., Havashidani Y., Sudo T., Hashimoto Y., et al. Prognostic impact of perioperative serum CA19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 2010, 17:2321-2329.
4. Takahashi H., Ohigashi H., Ishikawa O., Eguchi H., Gotoh K., Yamada T., et al. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg 2010, 251:461-469.
5. Raptis D.A., Fessas C., Belasyse-Smith P., Kurzawinski T.R. Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer. Surgeon 2010, 8:239-246.
6. Bernhard J., Dietrich D., Glimelius B., Hess V., Bodoky G., Scheithauer W., et al. Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. Br J Cancer 2010, 103:1318-1324.
7. Morizane C., Okusaka T., Morita S., Tanaka K., Ueno H., Kondo S., et al. Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma. Pancreas 2011, 40:415-421.
8. AJCC (American Joint Committee on Cancer) Cancer staging manual 2010, 117-121. Springer, New York. 7th ed. S.B. Edge, D.R. Byrd, C.C. Compton (Eds.).
9. WHO classification of tumors of the digestive system 2010, 381-398. WHO Press, Geneva (CH). 4th ed. F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise (Eds.).
10. Kaplan E.L., Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
11. Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977, 35:1-39.
12. Cox D.R. Regression models and life tables. J R Stat Soc 1972, 34:187-220.
13. Therneau T.M., Grambsch P.M. Modelling survival data: extending the Cox model 2000, Springer Verlag, New York, pp. 130-135.
14. Gobbi P.G., Valentino F., Berardi E., Tronconi C., Brugnatelli S., Luinetti O., et al. New insights into the role of age and carcinoembryonic antigen in the prognosis of colorectal cancer. Br J Cancer 2008, 98:328-334.
15. Poplin E., Feng Y., Berlin J., Rothenberg M.L., Hochster H., Mitchell E., et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009, 27:3778-3785.
16. Conroy T., Desseigne F., Ychou M., Bouché O., Guimbaud R., Bécouarn Y., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
17. Kim E.R., Bae S.Y., Lee K.H., Lee K.T., Son H.J., Rhee J.C., et al. Is health screening beneficial for early detection and prognostic improvement in pancreatic cancer?. Gut Liver 2011, 5:194-199.
18. Murr M.M., Sarr M.G., Oishi A.J., van Heerden J.A. Pancreatic cancer. CA Cancer J Clin 1994, 44:304-318.
19. Bramhall S.R., Allum W.H., Jones A.G., Allwood A., Cummins C., Neoptolemos J.P. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiologic study. Br J Surg 1995, 82:111-115.
20. Gilliam A.D., Lobo D.N., Rowlands B.J., Beckingham I.J. The " two week" target for the diagnosis of pancreatic carcinoma: an achievable aim?. Eur J Surg Oncol 2003, 29:575-579.
21. Yamaguchi K., Nishihara K., Tauneyoshi M. Non-icteric pancreas head carcinoma fares worse than icteric pancreas head carcinoma. J Surg Oncol 1992, 49:253-258.
22. Gillen S., Schuster T., Friess H., Kleef J. Palliative resection versus palliative bypass procedures in pancreatic cancer - a systematic review. Am J Surg 2011, [Epub: August 25].
23. Cronin-Fenton D.P., Erichsen R., Mortensen F.V., Dikinis S., Nørgaard M., Jacobsen J. Pancreatic cancer survival in central and northern Denmark from 1998 through 2009: a population-based cohort study. Clin Epidemiol 2011, 3(Suppl. 1):19-25.